Kraig Biocraft Laboratories, Inc. is a leading-edge biotechnology company focused on the development and commercialization of spider silk-based fibers. The company utilizes recombinant DNA technology to genetically engineer silkworms capable of producing silks with the properties of spider silk, which are known for their superior strength, elasticity, and durability. These advanced materials have potential applications across various industries, including medical, military, and textile sectors.

Kim Thompson

Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. engages in developing protein-based fibers using recombinant DNA technology for commercial applications in the technical textile and specialty fiber industries in the United States. The company's products are used in military and police applications for ballistic protection; industrial applications, including critical cables and abrasion/impact resistant components; safety equipment; and composite materials for the aero-space industry. Its products are also used in various markets, such as medical textiles, geotextiles, defense and military textiles, safe and protective clothing, filtration textiles, composites with textile structure, and functional and sportive textiles, as well as textiles used in buildings and transportation. The company was incorporated in 2006 and is headquartered in Ann Arbor, Michigan.

Kraig Biocraft Laboratories, Inc. (Trading Symbol: KBLB) is a fully reporting biotechnology company focused on the development and commercialization of spider silks. As a reporting company, our annual and quarterly reports to the SEC can be found on EDGAR and on this website. Our investments in genetic research are targeted for product development and innovative near-term solutions to meet the practical problems of our world.

Our genetic engineering research has succeeded in developing what many considered to be the holy grail of material science: A practical and cost-effective technology for producing recombinant spider silk based fibers on an industrial scale. We are moving rapidly to commercialize of our spider silk technology, which we believe will have a significant impact on the global textiles industry. At the same time we are continuing to work in cooperation with leading laboratories to create new stronger and more flexible spider silk based fibers with potentially broad applications for consumers and industry in the multi-billion dollar marketplace for textiles and performance polymers.

At Kraig, we are passionate about pioneering the research, development and commercialization of the next generation of high performance fibers based on genetic engineered spider silk. We are the world leader in our field of genetic research and product development.

Metric
Company Name	Kraig Biocraft Laboratories, Inc.
Symbol
MSH ID	COM:KRAIGLABS
Market	STOCKS
Sector	Technology
Industry	Biotechnology
Country	US
Stage
Employee Count	11
Website	kraiglabs.com
LinkedIn	kraig-biocraft-laboratories-inc-
Founders

Metric
Market Cap	141.22M
Enterprise Value
Monthly Web Traffic	1.17K
Web Traffic Growth	-0.57
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:KRAIGLABS

Kraig Biocraft Laboratories, Inc.

Last Close

0.09

22/11 20:00

Market Cap

141.22M

Beta: -

Volume Today

298.22K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue